Neurokinin 3 Receptor Antagonist Drug Class List

Drugs in Drug Class: Neurokinin 3 Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	9,987,274
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	9,422,299		Y	Y
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	8,871,761			Y
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes

Market dynamics and patent landscape for Neurokinin 3 receptor antagonists: exclusivity timelines, Orange Book status, Paragraph IV risk, and biosimilar/generic entry scenarios

Last updated: June 23, 2026

The neurokinin 3 receptor (NK3R) antagonist space is still early in broad commercial scale, with patent estates that are typically concentrated in (i) small-molecule active pharmaceutical ingredient (API) claims, (ii) salt/polymorph and formulation claims, and (iii) limited method-of-use claims tied to neuropsychiatric, sleep, and related CNS indications. The dominant market dynamic is that NK3R antagonists are being developed as differentiated CNS products, but the near-term competitive pressure comes from adjacent CNS therapies and from how quickly sponsors can secure line-of-extension patents around crystalline form, fixed-dose combinations, and clinical utility datasets that support additional label claims.

What patents protect NK3R antagonists, and how many active estates exist?
The “NK3R antagonist” category is not a single patent family universe. It is a constellation of program-specific estates anchored to different chemical scaffolds and different claim strategies (composition, process, and formulation). In practice, the defensible core is usually the chemical entity and its identified solid forms, with secondary protection around manufacturing processes and oral formulations.

How is patent coverage typically structured for NK3R antagonists?

Primary layers

• Composition of matter: API, including free base and salts (N-oxide is less common; hydrates are case-dependent).
• Solid state: specific polymorphs or solvates, including methods to prepare them.
• Formulation: oral dosage claims (immediate-release, extended-release) and excipient combinations that support stability and bioavailability.

Secondary layers

• Manufacturing/process: steps to make the API with defined temperatures, catalysts, purification steps, or crystallization conditions.
• Method of use: treatment of specific NK3R-mediated conditions, often with narrower claim scopes than composition claims.

Regulatory alignment layer

• Data exclusivity and pediatric exclusivity depend on FDA pathway and whether the drug is approved with qualifying exclusivity triggers. These periods can extend effective competition avoidance even after patent expiration.

What companies currently anchor NK3R antagonist patent estates?

Market participants typically include global CNS pharma and specialty developers that also manage broader neuropsychiatric pipelines. The patent estate map is program-by-program: the same company can carry multiple NK3R programs, but the enforceable claims are usually separated into distinct families by scaffold.

Net market impact: the “how many patents” answer is best modeled by counting families per approved product and by technology layer (composition vs solid form vs formulation). Without program-specific product names and patent lists, counting across the entire class is not actionable for filing strategy, licensing diligence, or litigation risk.

---

Which NK3R antagonists are approaching exclusivity loss, and when do patents expire?

Featured snippet answer: NK3R antagonist exclusivity loss timing is driven by the earliest filing date in the core composition family, then extended by later filings on solid forms, formulations, and label expansion, with effective launch timing also influenced by FDA exclusivity (where applicable).

How exclusivity timelines usually stack for NK3R antagonists

Most NK3R programs follow a stacked timeline:

1. Earliest priority date for the chemical entity (composition of matter).
2. Later priorities for solid state (polymorph/solvate) and formulation.
3. Later priorities for method of use or combinations once clinical data mature.
4. FDA exclusivity windows if triggered at approval.

Commercial dynamic: sponsors seek “evergreening” around solid forms and oral dosing platforms because these patents can be easier to defend than broad method-of-use claims, and they can support proprietary manufacturing and stability.

Where generic entry pressure tends to hit first

Generic launch risk accelerates when:

• The core composition patent set is near expiration.
• Solid-state patents expire or are easy to design around by selecting alternate polymorphs.
• Formulation patents are weak or not product-critical (hard to prove infringement if the generic uses a different release profile or different excipient system).

How it plays out for business: the most likely first wave is not the earliest API challenge; it is a challenge targeting the easiest-to-attack extension patents (solid form or formulation) that block generic manufacturing pathways.

---

What is the Orange Book status of NK3R antagonists, and which patents are Orange Book-listed?

Featured snippet answer: Orange Book status is product-specific. For NK3R antagonists, investors and litigators should treat each NDA as a separate IP estate and map Orange Book-listed patents by expiration date and by patent category (drug substance vs drug product vs method).

How to interpret Orange Book listings for NK3R antagonist risk models

For a risk model, categorize each Orange Book patent into:

• Drug substance patents: strongest infringement hook against an API challenge.
• Drug product patents: key for formulation generics and for design-around analysis.
• Method patents: depends on label alignment; if a generic’s intended use differs from the patented method-of-use claim scope, infringement arguments weaken.

Commercial dynamic: for CNS drugs, formulation and method claims can be strategically important because they can be tied to PK/PD outcomes and patient population definitions.

Constraint: the actual Orange Book listing numbers, patent codes, and expiration dates must be enumerated from the Orange Book database for each NK3R antagonist NDA. That product-level data is not provided in the prompt, so a complete and accurate Orange Book map cannot be produced here.

---

How strong is the patent estate for NK3R antagonists, and what makes estates vulnerable?

Featured snippet answer: NK3R estates tend to be strongest when they include multiple, independently asserted composition and solid-state patents with clear enabling disclosures. Vulnerability rises where extension patents depend on narrow solid forms or on formulation details that are easier to redesign.

Patent strength drivers (litigation-relevant)

• Independence of claims: if multiple families independently cover the same API or solid form, the generic design-around must change more than one variable.
• Claim breadth: broad composition claims reduce generic freedom; narrow claims shift litigation into factual disputes about salt identity, polymorph selection, and analytical characterization.
• Technology disclosure quality: weak enablement or unclear polymorph definitions increase invalidity and noninfringement leverage.

Patent weakness drivers

• Polymorph claims with unclear control of identity in manufacturing.
• Formulation claims that specify narrow excipient ratios or release-engineering conditions.
• Method-of-use claims that track a specific patient subgroup or dosing regimen that is hard to replicate in a generic ANDA label.

Business impact: buyers and licensees should weigh enforceability, not just count of patents. For CNS, “how defensible is analytical proof” matters because polymorph and dissolution behavior are contested.

---

What patent litigation affects NK3R antagonists, including Paragraph IV filings and settlements?

Featured snippet answer: NK3R litigation for NK3R antagonists follows the standard ANDA pathway logic: Paragraph IV challenges usually target the most recently listed extension patents that block generic approval. Settlement terms determine when generic labels can launch.

How to structure an NK3R litigation intelligence view

For each NK3R NDA with any Paragraph IV activity:

• List the defendant ANDA filers.
• Identify which Orange Book patents were challenged (drug substance vs drug product vs method).
• Capture district court venue and case number.
• Record court outcomes and any interim injunctions.
• Capture settlement agreements with agreed launch dates and permissible “carve-outs” (for example, partial settlements by patent subset).

Constraint: the prompt does not include product names, Orange Book patent lists, or court dockets. A complete litigation map with case numbers, challenged patents, and settlement dates cannot be generated without that underlying dataset.

---

What generic entry risks exist for NK3R antagonists, and what launch scenarios are most likely?

Featured snippet answer: Generic entry scenarios typically split into (i) successful design-around of formulation and solid-state patents, and (ii) timed ANDA approvals post-expiration with label carving that avoids method-of-use infringement.

Risk scenario matrix for NK3R antagonists

Scenario A: ANDA approval near core patent expiration

• Generic challenges extension patents but seeks approval after earliest expiration.
• Risk depends on injunction likelihood and whether the generic’s API matches a claimed salt/polymorph.

Scenario B: Design-around solid-state patents

• Generic selects a different polymorph/solvate or uses a different salt form.
• Risk depends on whether the claims cover alternative forms or include “structure-dependent” coverage language.

Scenario C: Formulation redesign

• Generic uses different release profile or excipient system.
• Risk depends on formulation claim specificity and how strictly infringement is proven via dissolution and composition testing.

Scenario D: Label carving to avoid method-of-use claims

• Generic’s label omits the patented indication or omits a dosing regimen.
• Risk depends on whether method claims require the generic to intend the patented use and whether FDA approval aligns with the remaining label language.

Commercial dynamic: CNS drug launch timing is also shaped by FDA review speed, bioequivalence study time, and potential citizen petitions or REMS complications where applicable.

---

How do NK3R antagonists compare with other neurokinin receptor classes on IP and market access?

NK3R antagonists sit within a broader neurokinin receptor strategy space that includes NK1R and NK2R antagonists and multi-target CNS approaches. In market terms, NK3R differentiation is driven by therapeutic hypothesis fit (sleep, affect, neuropsychiatric symptom clusters) and safety/tolerability profile.

IP comparison themes

• NK3R programs often rely on composition and solid-state chemistry with standard oral formulation layers.
• Multi-target CNS strategies frequently generate broader method-of-use and combination claims, but those claims can be narrower in practice due to label specificity.

Business lens: NK3R IP is often easier to map to scaffold-based families, while combination and regimen claims can create complex infringement theories tied to label language and real-world prescribing patterns.

---

What formulation patents and manufacturing method barriers protect NK3R antagonists?

Featured snippet answer: The main formulation barriers for NK3R antagonists are polymorph or salt identity control, dissolution and bioavailability performance, and manufacturing steps that yield a reproducible solid state.

Typical formulation and manufacturing claim targets

• Crystalline form specifications tied to XRD patterns and defined particle size distributions.
• Solvate/hydrate claims with specific drying/conditioning parameters.
• Compositions with defined excipient classes and ratios designed to manage pH-dependent solubility.
• Extended-release matrices with defined polymer systems and release kinetics.

Manufacturing bottlenecks that matter in litigation

• Whether the generic’s process inevitably yields the same solid state.
• Whether the API characterization methods in the patent are reproducible across manufacturing sites.
• Whether analytical tests can distinguish polymorphs reliably from batch-to-batch variability.

Commercial impact: manufacturing and QC prove infringement or noninfringement more than generic “paper” equivalence.

---

How do FDA pathways, exclusivity, and REMS affect NK3R antagonist market timing?

Featured snippet answer: FDA pathway choices determine whether data exclusivity blocks generic entry even after some patents expire. REMS, if required, can also slow competitive ramp.

Exclusivity levers relevant to NK3R antagonists

• New chemical entity status (5-year data exclusivity) where applicable.
• Orphan drug exclusivity (7-year) if designated.
• Pediatric exclusivity (6-month extension) tied to qualifying adult and pediatric studies.
• Patent term adjustments and patent term extensions depend on US regulatory filing timelines and statutes.

Business impact: the most time-sensitive driver for a launch or challenge is the earliest expiration of the Orange Book “blocking” patents plus any concurrent FDA exclusivity.

Constraint: without specific NK3R NDA identifiers, FDA pathway and exclusivity triggers cannot be itemized.

---

Key takeaways

1. NK3R antagonist IP is scaffold-based and usually centered on composition plus solid-state and oral formulation extensions that support manufacturing control and bioavailability performance.
2. Generic entry risk for NK3R drugs is most likely to emerge through challenges to extension patents (solid form and drug product) rather than immediate attack on the earliest composition family.
3. Orange Book status and patent category mapping are the fastest path to identifying “blocking” patents and likely Paragraph IV targets, but product-level NDA/patent data is required to enumerate specifics.
4. Litigation leverage in NK3R antagonists often hinges on analytical proof of polymorph/salt identity and on whether the generic’s formulation and label align with method-of-use claim scope.

---

FAQs

1. What types of NK3R antagonist patents are most commonly listed as Orange Book drug product patents?
2. Which NK3R antagonist claim themes are hardest for generics to design around: polymorph, salt form, or extended-release formulation?
3. How do label carving strategies work for NK3R antagonists with method-of-use patents?
4. What FDA exclusivity triggers most affect timing for NK3R antagonist generic approval under the ANDA pathway?
5. What settlement terms typically control launch dates in NK3R antagonist Paragraph IV cases?

---

References

No sources were provided in the prompt, and no product-specific NDA, Orange Book, FDA exclusivity, or litigation docket data was included. As a result, no numbered reference list can be generated without violating the requirement to produce a complete and accurate response.